Appointed
John McAdory
Chief Operating Officer
ONCY ·
ONCOLYTICS BIOTECH INC
appointed John McAdory as Chief Operating Officer of the Company
Ready 8-Ks
22
Latest filing
August 18, 2026, 9:03 AM ET
Top materiality
0.85
Event mix
other_material ×13 · regulatory ×7 · leadership ×2
Sentiment
15 pos · 1 neg · 6 neu
Executive change
recent →
Recent 8-K filings for ONCY
Highest-materiality recent filing
Oncolytics reports 19.5-month median DOR in 2L RAS-mutant MSS mCRC; triples ORR vs SOC
- Pelareorep-based combo shows median duration of response 19.5 months in 2L KRAS-mutant MSS mCRC, vs historical 4–6 months.
- Objective response rate 33% with pelareorep+FOLFIRI+bevacizumab, tripling the 6-11% standard of care.
-
Oncolytics aligns with FDA on pivotal Part B expansion for REO 033 colorectal cancer study
FDA written feedback supports potential pivotal Part B expansion of REO 033 in 2L RAS-mutant MSS colorectal cancer.
-
Oncolytics Biotech receives Nasdaq delisting notice for bid price below $1.00
Received Nasdaq letter on July 20, 2026, for non-compliance with $1.00 minimum bid price rule.
-
Oncolytics Biotech receives FDA Fast Track for pelareorep in second-line anal cancer
FDA granted Fast Track for pelareorep + checkpoint inhibitor in inoperable/metastatic squamous cell anal carcinoma after prior therapy.
-
Oncolytics: FDA Type D meeting in Aug; half of REO 033 sites activated, >20 patients pre-identified
Company to hold Type D meeting with FDA in first half of August 2026 to discuss registrational design for REO 033 Part B.
-
USPTO issued patent covering pelareorep manufacturing process, expected protection into 2044.
-
Oncolytics reports 19.5-month median DOR in 2L RAS-mutant MSS mCRC; triples ORR vs SOC
Pelareorep-based combo shows median duration of response 19.5 months in 2L KRAS-mutant MSS mCRC, vs historical 4–6 months.
-
Oncolytics secures FDA alignment on pivotal anal cancer study for pelareorep
FDA agreed on a randomized controlled pivotal trial design for pelareorep in post-first-line metastatic SCAC, targeting accelerated and full approval.
-
Oncolytics Biotech enters ATM agreement for up to $75M common stock offering
Agreement with Jefferies LLC allows sale of up to $75M in common stock at market prices.
-
Pelareorep data at AACR: 62% ORR in pancreatic cancer; TLS formation in breast cancer
GOBLET cohort 1: 62% objective response rate in first-line mPDAC, more than double historical chemotherapy alone.
-
Randomized Phase 2 study (REO 033) of pelareorep + bevacizumab + FOLFIRI vs bevacizumab + FOLFIRI in 30 patients per arm.
-
Oncolytics prioritizes SCAC and CRC registration studies; GOBLET enrollment closed
Concluded enrollment in GOBLET gastrointestinal study; now focusing on registrational studies in squamous cell anal cancer (SCAC) and metastatic colorectal cancer (CRC).
-
FDA Fast Track Designation for pelareorep + bevacizumab + FOLFIRI in second-line KRAS-mutant MSS metastatic colorectal cancer.
-
Oncolytics appoints EVP John McAdory and VP Biostatistics Yujun Wu, grants inducement awards
John McAdory named EVP Strategy & Operations; previously VP Clinical Ops at CG Oncology (Nasdaq: CGON).
-
GOBLET Cohort 4: 4/14 evaluable third-line anal cancer patients responded (ORR 29%), 2 CRs, 2 PRs; median DOR ~17 months vs historical ~10%.
Executive changes
Appointed
Stephen Glover
Director
ONCY ·
ONCOLYTICS BIOTECH INC
appointed Stephen Glover as the ninth director of the Board
Materiality & sentiment trend
Max materiality 0.85 · Median 0.65 · Most common event other_material